Valeant Climbs to Its Highest Level in More Than a Year

Don’t look now, but Valeant Pharmaceuticals International Inc. is at its highest level in more than a year.

This former favorite of Bill Ackman, which was attracting price targets above $300 in mid-2015 before losing most of its value, has climbed more than 75 percent since the end of October as the drugmaker prepares to begin sales this month of its new glaucoma treatment, Vyzulta. In addition, the U.S. FDA will decide by December 27 whether to approve the company’s Luminesse for ocular redness.